193 related articles for article (PubMed ID: 31768996)
21. [A Case of Unresectable Pancreas Cancer with 32 Months Survival after Chemotherapy].
Amagasa H; Fukuda A; Yamada A; Kakuta R; Kajiyama D; Kawaguchi M; Shibuya G; Maeda S; Motoyama K; Ganno H; Imai K; Ami K; Iida S; Andou M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2417-2419. PubMed ID: 30692483
[TBL] [Abstract][Full Text] [Related]
22. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
23. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
25. Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
Vicente E; Quijano Y; Ielpo B; Duran H
Surg Oncol; 2017 Sep; 26(3):276-277. PubMed ID: 29804945
[TBL] [Abstract][Full Text] [Related]
26. [A Case of Conversion Surgery after Long-Term Chemotherapy for Pancreatic Cancer with Peritoneal Metastasis].
Enoki M; Gotoh K; Sakai K; Toshiyama R; Yanagisawa K; Kawai K; Miyo M; Takahashi Y; Hamakawa T; Doi T; Takeno A; Katoh T; Takami K; Hirao M
Gan To Kagaku Ryoho; 2023 Jan; 50(1):87-89. PubMed ID: 36759995
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer.
Ohata K; Fujii H; Sadaka S; Kato-Hayashi H; Iihara H; Kobayashi R; Uemura S; Iwashita T; Shimizu M; Suzuki A
Anticancer Res; 2021 Jul; 41(7):3643-3648. PubMed ID: 34230162
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
29. [Conversion Surgery for Pancreatic Head Cancer with Peritoneal Dissemination Following Chemotherapy for Two Years - A Case Report].
Hatsuzawa Y; Mizuma M; Motoi F; Hata T; Iseki M; Takadate T; Ohtsuka H; Sakata N; Morikawa T; Nakagawa K; Hayashi H; Naitoh T; Kanno A; Shimosegawa T; Unno M
Gan To Kagaku Ryoho; 2018 Feb; 45(2):347-349. PubMed ID: 29483443
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
[TBL] [Abstract][Full Text] [Related]
31. [A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Kimura H; Fushida S; Mukawa A
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1191-4. PubMed ID: 19620816
[TBL] [Abstract][Full Text] [Related]
32. [A Case of Gemcitabine and Nab-Paclitaxel Therapy for Multiple Metastatic Pancreatic Cancer].
Takashima Y; Shibamoto J; Kawamura Y; Nishida M; Hiramoto H; Ochi F; Tsujiura M; Nakashima S; Fujiyama J; Masuyama M
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1826-1828. PubMed ID: 29394789
[TBL] [Abstract][Full Text] [Related]
33. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
[TBL] [Abstract][Full Text] [Related]
34. [A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
Kyakumoto Y; Takadate T; Mizuma M; Hata T; Iseki M; Ohtsuka H; Sakata N; Nakagawa K; Morikawa T; Hayashi H; Motoi F; Naitoh T; Kanno A; Shimosegawa T; Unno M
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1880-1882. PubMed ID: 29394807
[TBL] [Abstract][Full Text] [Related]
35. Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine.
Boeck S; Haas M; Kruger S; Heinemann V
In Vivo; 2014; 28(6):1189-92. PubMed ID: 25398821
[TBL] [Abstract][Full Text] [Related]
36. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Alvarez R; Musteanu M; Garcia-Garcia E; Lopez-Casas PP; Megias D; Guerra C; Muñoz M; Quijano Y; Cubillo A; Rodriguez-Pascual J; Plaza C; de Vicente E; Prados S; Tabernero S; Barbacid M; Lopez-Rios F; Hidalgo M
Br J Cancer; 2013 Aug; 109(4):926-33. PubMed ID: 23907428
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
38. A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Hasegawa R; Okuwaki K; Kida M; Yamauchi H; Kawaguchi Y; Matsumoto T; Kaneko T; Miyata E; Uehara K; Iwai T; Watanabe M; Kurosu T; Imaizumi H; Ohno T; Koizumi W
Int J Clin Oncol; 2019 Dec; 24(12):1574-1581. PubMed ID: 31309381
[TBL] [Abstract][Full Text] [Related]
39. [A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine].
Miyazaki K; Hayashi H; Ishida M; Ohtsuka H; Mizuma M; Nakagawa K; Morikawa T; Motoi F; Kamei T; Shinoto M; Yamada S; Takiyama H; Unno M
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2266-2268. PubMed ID: 33468929
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
